| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
PHA-680632
|
398493-79-3 |
PHA-68632
|
CS-411;N-(2,6-二乙基苯基)-4,6-二氢-3-[[4-(4-甲基-1-哌嗪基)苯甲酰基]氨基]吡咯并[3,4-C]吡唑-5(1H)-甲酰胺;PHA-680632;PHA680632;PHA 680632
|
C28H35N7O2 |
501.62 | |
|
JNJ-7706621
|
443797-96-4 |
JNJ-776621
|
|
C15H12F2N6O3S |
394.36 | |
|
GW 5074
|
220904-83-6 |
GW574
|
(3Z)-3-[(3,5-DIBROMO-4-HYDROXYPHENYL)METHYLIDENE]-5-IODO-1H-INDOL-2-ONE;GW 5074;GW-5074;GW5074;GW-5074;GW 5074;3-(3,5-二溴-4-羟基苯亚甲基)-5-碘-1,3-二氢吲哚-2-酮
|
C15H8Br2INO2 |
520.94 | |
|
3-[2,4-dimethyl-5-[(E)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
|
252916-29-3 |
orantinib
|
5-[(1,2-二氢-2-氧代-3H-吲哚-3-亚基)甲基]-2,4-二甲基-1H-吡咯-3-丙酸;5-[(1,2-二氢-2-氧代-3H-吲哚-3-基)甲基]-2,4-二甲基-1H-吡咯-3-丙酸;
|
C18H18N2O3 |
310.36 | |
|
Ispinesib
|
336113-53-2 |
伊斯平斯
|
伊匹尼塞;ISPINESIB;SB-715992;SB715993;伊斯平斯;(抗癌类)伊斯平斯
|
C30H33ClN4O2 |
517.08 | |
|
YO-01027
|
209984-56-5 |
YO127
|
YO01027;N-[(1S)-2-[[(7S)-6,7-二氢-5-甲基-6-氧代-5H-二苯并[B,D]氮杂卓-7-基]氨基]-1-甲基-2-氧代乙基]-3,5-二氟苯乙酰胺;Γ-分泌酶抑制剂;YO-01027-分泌酶抑制剂;二苯并氮卓,Γ-SECRETASE 抑制剂;二苯并氮卓;CS-366;YO-01027;YO01027;DIBENZAZEPINE;DESHYDROXY LY 411575;DBZ
|
C26H23F2N3O3 |
463.49 | |
|
GSK1070916
|
942918-07-2 |
GSK17916
|
GSK1070916;GSK-1070916;GSK 1070916;GSK1070916;GSK 1070916;CS-364;N'-[4-[4-[2-[3-[(二甲基氨基)甲基]苯基]-1H-吡咯并[2,3-B]吡啶-4-基]-1-乙基-1H-吡唑-3-基]苯基]-N,N-二甲基脲
|
C30H33N7O |
507.63 | |
|
Telatinib
|
332012-40-5 |
替拉替尼
|
|
C21H18ClN5O2 |
407.85292 | |
|
GSK 1210151A (I-BET151)
|
1300031-49-5 |
I-BET151 (GSK121151A)
|
CS-1920;GSK-1210151A;IBET151;I-BET-151;I BET 151;IBET-151;IBET 151;GSK 1210151A;CS-358;IBET151;I-BET-151;I BET 151;IBET-151;IBET 151;7-(3,5-二甲基-4-异唑基)-1,3-二氢-8-甲氧基-1-[(1R)-1-(2-吡啶基)乙基]-2H-咪唑并[4,5-C]喹啉-2-酮;7-(3,5-二甲基-4-异噁唑基)-1,5-C]喹啉-2-酮;1-(2-吡啶基)乙基]-2H-咪唑并[4,5-二甲基异恶唑-4-基)-8-甲氧基-1-((R)-1-(吡啶-2-基)乙基)-1H-咪唑并[4,5-C]喹啉-2(3H)-酮
|
C23H21N5O3 |
415.44454 | |
|
FADROZOLE HYDROChloride
|
102676-31-3 |
盐酸法倔唑
|
FADROZOLE (HYDROCHLORIDE);CGS 16949A;法倔唑盐酸盐;CS-356
|
C14H13N3.ClH |
259.739 | |
|
AC480
|
714971-09-2 |
AC48 (BMS-599626)
|
BMS599626;AC-480;BMS 599626 (AC480);AC-480;BMS-599616;[4-[[1-[(3-氟苯基)甲基]-1H-咪唑-5-基]氨基]-5-甲基吡咯[2,1-F][1,2,4]三嗪-6-基]-氨基甲酸-(3S)-3-吗啉甲酯
|
C27H27FN8O3 |
530.561 | |
|
BX-912
|
702674-56-4 |
BX-912
|
N-[3-[[5-溴-4-[[2-(1H-咪唑-5-基)乙基]氨基]-2-嘧啶基]氨基]苯基]-1-吡咯烷甲酰胺;CS-339
|
C20H23BrN8O |
471.35 | |
|
SB216763
|
280744-09-4 |
SB216763
|
3-(2,4-二氯苯基)-4-(1-甲基-1H-吲哚-3-基)-1H-吡咯-2,5-二酮
|
C19H12Cl2N2O2 |
371.21678 | |
|
6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline
|
1022150-57-7 |
SGX-523
|
CS-331;6-[[6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-B]哒嗪-3-基]硫基]喹啉;6-[[6-(1-甲基-1H-吡唑-4-基)-1,4-噻唑并[4,3-B]吡嗪-3-基]硫代]喹啉;SGX-523;SGX523;SGX 523
|
C18H13N7S |
359.42 | |
|
Bardoxolone methyl (RTA 402)
|
218600-53-4 |
甲基巴多索隆
|
RTA-402; NSC-713200; TP-155C; METHYL-CDDO; METHYLCDDO;BARDOXOLONE METHYL;BARDOXOLONE METHYL;NSC 713200; RTA 402;2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯 1G;2-氰基-3,9(11)-二烯-28-酸甲酯;甲基巴多索隆,一种有效的 NRF2 激活剂,具有抗氧化、抗炎等功效;CS-322;甲基巴多索隆
|
C32H43NO4 |
505.68812 | 606-850-4 |
|
TCS JNK 5a
|
312917-14-9 |
SC-22671
|
JNK INHIBITOR IX;TCSJNK-5A);SC-202671>98%;SC-202671;N-(3-氰基-4,5,6,7-四氢苯并[B]噻吩-2-基)-1-萘甲酰胺
|
C20H16N2OS |
332.41884 | |
|
NF 279
|
202983-32-2 |
可溶性品红-279
|
可溶性品红-279;8,8'-[羰基双(亚氨基-4,1-亚苯基羰基亚氨基-4,1-亚苯基羰基亚氨基)]双-1,3,5-萘三磺酸钠盐;CS-319
|
C49H30N6Na6O23S6 |
1401.12 | |
|
AG-490
|
133550-30-8 |
酪氨酸磷酸化抑制剂AG 49
|
AG490,AG-490;酪氨酸激酶抑制剂AG 490;CS-316;AG 490;TYRPHOSTIN AG 490;AG490;ZINC02557947;AG-490 (TYRPHOSTIN B42);AG-490,一种EGFR抑制剂
|
C17H14N2O3 |
294.3 | |
|
Compound 401
|
168425-64-7 |
COMPOUND 41
|
2-(吗啉-4-基)嘧啶并[2,1-A]异喹啉-4-酮;2-吗啉基-4H-嘧啶并[2,1-A]异喹啉-4-酮
|
C16H15N3O2 |
281.314 | |
|
dronedarone
|
141626-36-0 |
决奈达隆
|
龙胆酮杂质;决奈达隆;决奈达隆 (盐酸盐 CAS 141625-93-6 );决奈达龙;决奈达隆1;决萘达隆;CS-295;DRONEDARONE(决萘达隆中间体)
|
C31H44N2O5S |
556.76 |
药智官方微信
药智官方微博
